GIERER, DANIEL SCOTT,吉儿 丹尼尔,吉兒 丹尼爾,MORGADO, JAMES ERIC,摩卡多 詹姆士,摩卡多 詹姆士,MURPHY, BRENDAN JOHN,墨菲 布莱顿,墨菲 布萊頓,SIMMONS, DARYL MICHAEL,塞门斯 戴瑞尔,塞門斯 戴瑞爾
申请号：
TW101135312
公开号：
TW201328725A
申请日:
2012.09.26
申请国别(地区):
TW
年份:
2013
代理人:
摘要：
The present invention relates to pharmaceutical compositions containing axitinib, which is known as N-methyl-2-[3-((E)-2-pyridin-2-yl-vinyl)-1H-indazol-6-ylsulfanyl]-benzamide or 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-E-[2-(pyridin-2-yl)ethenyl]indazole, or crystalline forms thereof, that protect axitinib from degradation, including photodegradation, as well as the therapeutic use of such compositions. The present invention also relates to novel photodegradants of axitinib.本發明關於防止阿西替尼(axitinib)降解(包括光降解)之藥學組成物,其含有阿西替尼(已知為N-甲基-2-[3-((E)-2-吡啶-2-基-乙烯基)-1H-吲唑-6-基氫硫基]-苯甲醯胺或6-[2-(甲基胺甲醯基)苯基氫硫基]-3-E-[2-(吡啶-2-基)乙烯基]吲唑)或其晶型,以及該等組成物之治療用途。本發明也關於阿西替尼之新穎光降解產物。
